🚀JUST ANNOUNCED: ATUM Launches the discoCHO™ Discovery Cell Line for Rapid and Robust Transient Production of Biologics with Manufacturing in Mind ATUM's new CHO-K1-based discoCHO cell line enables robust transient therapeutic protein expression displaying critical quality attributes similar to those of the stable CHO-K1 manufacturing cell line, miCHO-GS. This advancement in antibody production allows you to bring drugs to market faster, while mitigating risk. For more information on this exciting expansion of our industry-leading ecosystem, read the full release: https://hubs.li/Q02LpWVb0 #Biologics #AntibodyProduction #CellLineProduction #CHOK1
About us
ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.
- Website
-
http://www.atum.bio
External link for ATUM
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Newark, CA
- Type
- Privately Held
- Founded
- 2003
- Specialties
- Bioengineering, Genes, Proteins, and Cell Lines
Locations
-
Primary
Get directions
37950 Central Court
Newark, CA 94560, US
Employees at ATUM
Updates
-
This #WorldFoodDay, we're proud to be part of the engineering team behind CHY-MAX® Supreme, an enzyme that enables cheesemakers to produce more cheese from the same amount of milk. Whether increasing safety, sustainability, or value, ATUM is proud to support the efforts of those working to feed the world.
-
-
ATUM reposted this
Had a fantastic Day 1 at the Festival of Biologics, and looking forward to Day 2! Hop on over to Booth #1224 to learn more about our Leap-In Transposase® technology, custom Antibody Services, and ATUM’s latest offering, discoCHO™—CHO-K1 for both discovery and development. #FOB2024 #DrugDevelopment #biologics
-
-
Had a fantastic Day 1 at the Festival of Biologics, and looking forward to Day 2! Hop on over to Booth #1224 to learn more about our Leap-In Transposase® technology, custom Antibody Services, and ATUM’s latest offering, discoCHO™—CHO-K1 for both discovery and development. #FOB2024 #DrugDevelopment #biologics
-
-
TODAY at Festival of Biologics | Tackling two tracks: Double the science, double the fun! Join Oren Beske in 'MC, Developability & Analytics' and Mario Pereira in 'Bispecifics & Multispecifics' to learn about leveraging transposase platforms for advance cell line development. Then stop by our booth (#1224) to get more details on how ATUM's Leap-In Transposase® platform can shave months off CMC timeline -- from transfection to RCB in ~10 weeks!
-
-
A panel moderated by ATUM's CIO and comp bio maestro Sridhar Govindarajan on "How to create an integrative 'AI Mindset' to deliver novel therapeutics," AND a fireside chat with newly minted Nobel Prize winner David Baker?! Sign us up now for Endpoints News' AI Day 2024 virtual event: https://hubs.li/Q02T33Ws0 #AI #ComputationalBiology #DrugDiscovery
-
-
✈️🇨🇭 Heading to the Festival of Biologics in Basel? Don't miss ATUM’s Oren Beske, PhD, Amalgamator of Business & Biology, and Mario Pereira, PhD, Director of Technology and Business Development presenting on the latest in cell line development. Set up a meeting with them or another ATUM expert now! ➡️ https://hubs.li/Q02T1MwP0 #FestivalOfBiologics #CellLineDevelopment #Biologics
-
-
With #biologics now dominating the market, bioprocessing will need to improve—and it's not just a quick AI fix, explains ATUM's CCO & Co-Founder Claes Gustafsson in the latest issue of The Medicine Maker (p. 19). Claes is proud to join over 100 #biotech experts celebrating the magazine's 10th Anniversary with a look back at the last decade in pharma and healthcare, and a peek forward at the big changes we can expect in the next ten years. Check out the full issue now: https://lnkd.in/gPKiMw5k #PharmaceuticalIndustry #DrugDevelopment #Innovation #ManufacturingTrends http://atum.bio
-
#DYK Liver cancer claims the lives of ~30,000 American adults annually and a leading cause of cancer death globally. Dysregulation of master regulator c-MYC (MYC) plays a central role in hepatocellular carcinoma (HCC) and other cancers but has remained an elusive target for therapeutic intervention. This Liver Cancer Awareness Month, we're taking a look at a recent Nature Communications article in which a team from Omega Therapeutics shows epigenomic mRNA leads to genomic methylation and downregulation of regulator cMYC, and causes significant reduction of liver cancer in preclinical model. The team used DNA binding proteins made from ATUM genes. https://hubs.li/Q02SmqxS0 #OctoberIs4Livers #ThinkLiverThinkLife
-
-
Excited to be a Gold Sponsor for the upcoming Festival of Biologics in Basel, Switzerland! With two speakers lined up—Oren Beske and Mario Pereira, we're looking forward to sharing insights on the latest in bispecifics, multispecifics, and developability and analytics. Are you attending? Let's connect! Set up a time to meet with one of our experts now: https://hubs.li/Q02RYxWJ0 #Biologics #FestivalofBiologics #Switzerland #PharmaIndustry #Networking
-